Cargando…

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator

The sphingosine‐1‐phosphate 1 receptor (S1P(1R)) is expressed by lymphocytes, dendritic cells, and vascular endothelial cells and plays a role in the regulation of chronic inflammation and lymphocyte egress from peripheral lymphoid organs. Ozanimod is an oral selective modulator of S1P(1R) and S1P(5...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran, Jonathan Q., Hartung, Jeffrey P., Peach, Robert J., Boehm, Marcus F., Rosen, Hugh, Smith, Heather, Brooks, Jennifer L., Timony, Gregg A., Olson, Allan D., Gujrathi, Sheila, Frohna, Paul A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Pharmacokinetics/Pharmacodynamics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516232/ https://www.ncbi.nlm.nih.gov/pubmed/28398597 http://dx.doi.org/10.1002/jcph.887

Ejemplares similares

Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study
por: Tran, Jonathan Q., et al.
Publicado: (2017)

Pharmacokinetics and Concentration‐Response of Dupilumab in Patients With Seasonal Allergic Rhinitis
por: Kamal, Mohamed A., et al.
Publicado: (2022)

Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects
por: Cohen-Barak, Orit, et al.
Publicado: (2015)

Investigation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of a Long-Acting α-MSH Analog in Healthy Overweight and Obese Subjects
por: Royalty, Jane E, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease
por: Hohlfeld, JM, et al.
Publicado: (2014)

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia
por: Xiao, Alan J., et al.
Publicado: (2016)

Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteers
por: Tinsley, Jon, et al.
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects
por: Krishna, Rajesh, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia
por: Zhang, Xiaoping, et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout
por: Kankam, Martin, et al.
Publicado: (2018)

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti‐CD28 Domain Antibody Antagonist in Healthy Subjects
por: Shi, Rong, et al.
Publicado: (2016)

A Randomized, Single‐Center, Double‐Blind, Placebo‐Controlled Multiple‐Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects
por: Matsuno, Kumi, et al.
Publicado: (2018)

Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti‐CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases
por: Schwabe, Christian, et al.
Publicado: (2018)

A Phase 1, Multiple‐Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis
por: Kobayashi, Kiyonori, et al.
Publicado: (2018)

Toward Better Understanding of Insulin Therapy by Translation of a PK‐PD Model to Visualize Insulin and Glucose Action Profiles
por: Schneck, Karen, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
por: Abdallah, Hisham, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial
por: Shoaf, Susan E., et al.
Publicado: (2017)

A Novel NF‐κB Inhibitor, Edasalonexent (CAT‐1004), in Development as a Disease‐Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects
por: Donovan, Joanne M., et al.
Publicado: (2017)

Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials
por: van der Aar, Ellen, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition
por: Sun, Steven, et al.
Publicado: (2022)

Effects of High‐ and Low‐Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator
por: Tran, Jonathan Q., et al.
Publicado: (2017)

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS
por: Harris, Sarah, et al.
Publicado: (2020)

Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction
por: Schalekamp, Tom, et al.
Publicado: (2007)

The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia
por: Krysiak, Robert, et al.
Publicado: (2011)

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
por: Ruf, Peter, et al.
Publicado: (2010)

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
por: Clemens, Andreas, et al.
Publicado: (2012)

Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation
por: Tanigawara, Yusuke, et al.
Publicado: (2011)

Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension
por: Smith, William B., et al.
Publicado: (2012)

A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects
por: Kempsford, Rodger, et al.
Publicado: (2014)

Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review
por: Atkinson, Hartley C., et al.
Publicado: (2015)

Bilastine vs. hydroxyzine: occupation of brain histamine H(1)-receptors evaluated by positron emission tomography in healthy volunteers
por: Farré, Magí, et al.
Publicado: (2014)

The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects
por: Langenickel, Thomas H., et al.
Publicado: (2016)

Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in human platelets
por: Massimi, Isabella, et al.
Publicado: (2014)

Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients
por: Misiak, Błażej, et al.
Publicado: (2014)

Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone
por: Lal, Ritu, et al.
Publicado: (2015)

Statin use decreases coagulation in users of vitamin K antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
por: Coffey, Greg, et al.
Publicado: (2016)

Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults
por: Shoaf, Susan E., et al.
Publicado: (2017)

Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency
por: Tortorici, Michael A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_odm8ka02ftsfbgecjhj3kctb7b